Brief: ContraFect Announces Independent Dsmb Recommends Exebacase Phase 3 Disrupt Study Be Stopped For Futility Following Interim Analysis
13/07/2022 21:16
July 13 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES INDEPENDENT DSMB RECOMMENDS EXEBACASE
PHASE
3 DISRUPT STUDY BE STOPPED FOR FUTILITY FOLLOWING INTERIM
ANALYSIS
* CONTRAFECT CORP- DSMB RECOMMENDED THAT TRIAL BE STOPPED
BECAUSE
CONDITIONAL POWER OF STUDY WAS BELOW PRE-SPECIFIED THRESHOLD FOR
FUTILITY
* CONTRAFECT CORP- PLANS TO PROVIDE FURTHER DETAILS
REGARDING
DEVELOPMENT OF EXEBACASE FOLLOWING COMPLETION OF ITS OWN
ANALYSIS OF ACCRUED STUDY DATA
Source text for Eikon: ID:nGNX1P2g0l
Further company coverage: CFRX.O
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370